Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine.

Abstract	Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD). Fifteen patients had Stage IV disease and 11 had systemic symptoms. Although hematologic toxicity was considerable, there was no drug related mortality. Eight patients achieved a complete remission (CR), and five are currently in a continuous CR of five, 24, 30, 34, and 36 months duration, respectively. An additional patient had a 30-month CR and relapsed with localized lymphadenopathy and is currently disease-free following involved-field radiotherapy 46 months from initiation of VABCD. This study suggests that long-term disease-free survival and potential cure can be achieved with VABCD in MOPP-refractory Hodgkin's disease.
Authors	L H Einhorn, S D Williams, E E Stevens, W H Bond, L Chenoweth
Journal	Cancer (Cancer) Vol. 51 Issue 8 Pg. 1348-52 (Apr 15 1983) ISSN: 0008-543X [Print] United States
PMID	6186356 (Publication Type: Clinical Trial, Journal Article)
Chemical References	Antineoplastic Agents Bleomycin Procarbazine Mechlorethamine Vincristine Vinblastine Lomustine Dacarbazine Doxorubicin Prednisone
Topics	Adolescent Adult Agranulocytosis (chemically induced) Antineoplastic Agents (administration & dosage, adverse effects) Antineoplastic Combined Chemotherapy Protocols Bleomycin (administration & dosage, adverse effects) Clinical Trials as Topic Dacarbazine (administration & dosage, adverse effects) Doxorubicin (administration & dosage, adverse effects) Drug Resistance Drug Therapy, Combination Female Hodgkin Disease (drug therapy) Humans Lomustine (administration & dosage, adverse effects) Male Mechlorethamine (administration & dosage) Middle Aged Prednisone (administration & dosage) Procarbazine (administration & dosage) Prognosis Thrombocytopenia (chemically induced) Vinblastine (administration & dosage, adverse effects) Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!